David M Gershenson
Overview
Explore the profile of David M Gershenson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
251
Citations
9244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hollis R, Elliott R, Dawson J, Ilenkovan N, Matthews R, Stillie L, et al.
Gynecol Oncol
. 2024 Apr;
186:42-52.
PMID: 38582027
Background: Low grade serous ovarian carcinoma (LGSOC) is a distinct histotype of ovarian cancer characterised high levels of intrinsic chemoresistance, highlighting the urgent need for new treatments. High throughput screening...
12.
How J, Flores Legarreta A, Handley K, Fellman B, Foster K, Glassman D, et al.
Am J Obstet Gynecol
. 2024 Jan;
230(5):544.e1-544.e13.
PMID: 38191019
Background: Few studies have evaluated the role of cytoreductive surgery in patients with recurrent adult granulosa cell tumors of the ovary. Despite a multitude of treatment modalities in the recurrent...
13.
Hinchcliff E, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, et al.
Cancer
. 2023 Nov;
130(7):1061-1071.
PMID: 38009662
Background: Single-agent immune checkpoint inhibitors (ICIs) have demonstrated limited responses in recurrent ovarian cancer; however, 30%-40% of patients achieve stable disease. The primary objective was to estimate progression-free survival (PFS)...
14.
Grisham R, Slomovitz B, Andrews N, Banerjee S, Brown J, Carey M, et al.
Int J Gynecol Cancer
. 2023 Aug;
33(9):1331-1344.
PMID: 37591609
Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects younger...
15.
Matsuo K, Matsuzaki S, Maeda M, Rau A, Yoshihara K, Tamura R, et al.
JAMA Netw Open
. 2023 Jun;
6(6):e2318602.
PMID: 37326992
Importance: Randomized clinical trials examining the effectiveness of neoadjuvant chemotherapy (NACT) for advanced ovarian cancer predominantly included patients with high-grade serous carcinomas. The use and outcomes of NACT in less...
16.
Praiss A, Miller A, Smith J, Lichtman S, Bookman M, Aghajanian C, et al.
Gynecol Oncol
. 2023 May;
174:213-223.
PMID: 37229879
Objective: To determine the effects of using National Comprehensive Cancer Network (NCCN) guidelines to estimate renal function on carboplatin dosing and explore adverse effects associated with a more accurate estimation...
17.
Sia T, Tew W, Purdy C, Chi D, Menzin A, Lovecchio J, et al.
Gynecol Oncol
. 2023 May;
173:130-137.
PMID: 37148580
Objective: To assess the effect of age on overall survival (OS) in women with ovarian cancer receiving chemotherapy. Secondary objectives were to describe the effect of age on treatment compliance,...
18.
Khlebus E, Vuttaradhi V, Welte T, Khurana N, Celestino J, Beird H, et al.
Mol Cancer Res
. 2023 Apr;
21(5):483-494.
PMID: 37068116
Implications: Recurrent aGCTs exhibit alterations in hormone pathway gene expression as well as decreased infiltration of cancer-associated fibroblasts, suggesting dual roles for hormonal signaling and TME remodeling underpinning disease relapse.
19.
Foster K, Flores Legarreta A, Kamat R, Handley K, Glassman D, How J, et al.
Am J Obstet Gynecol
. 2023 Mar;
228(6):724.e1-724.e9.
PMID: 36907533
Background: The optimal treatment of recurrent ovarian granulosa cell tumors is not known. Preclinical studies and small case series have suggested direct antitumor activity of gonadotropin-releasing hormone agonists in the...
20.
Wong K, Bateman N, Ng C, Tsang Y, Sun C, Celestino J, et al.
J Transl Med
. 2022 Dec;
20(1):606.
PMID: 36528667
Background: Low-grade serous ovarian cancer (LGSOC) is a rare disease that occurs more frequently in younger women than those with high-grade disease. The current treatment is suboptimal and a better...